Processa Pharmaceuticals (PCSA) Total Non-Current Liabilities (2012 - 2015)
Processa Pharmaceuticals' (PCSA) quarterly Total Non-Current Liabilities came in at $27507.0 in Q3 2015, down 98.61% YoY from $2.0 million in Q3 2014, and down 73.79% on a QoQ basis from $104948.0 in Q2 2015.
Processa Pharmaceuticals (PCSA) Total Non-Current Liabilities (2012 - 2015) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 4 years of Total Non-Current Liabilities data on file, last reported at $27507.0 in Q3 2015.
- Quarterly Total Non-Current Liabilities fell 98.61% year-over-year to $27507.0 in Q3 2015, while the trailing twelve-month figure through Sep 2015 was $27507.0 (down 98.61% YoY) and the FY2014 annual result came in at $494066.0, up 239.66% from the prior year.
- Total Non-Current Liabilities fell to $27507.0 in Q3 2015, from $104948.0 in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $2.0 million in Q3 2014 to a low of $27507.0 in Q3 2015.
- A 4-year average of $583047.3 and a median of $156198.0 in 2013 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2014 — Total Non-Current Liabilities soared 1633.87% — and 2015, when it plunged 98.61%.
- Tracing PCSA's Total Non-Current Liabilities over 4 years: stood at $606158.0 in 2012, then plunged by 76.0% to $145458.0 in 2013, then surged by 239.66% to $494066.0 in 2014, then tumbled by 94.43% to $27507.0 in 2015.
- The last three Total Non-Current Liabilities figures came in at $27507.0 (Q3 2015), $104948.0 (Q2 2015), and $119446.0 (Q1 2015), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 9.32 Bn |
| 10 | Processa Pharmaceuticals | 5.72 Mn | 5.72 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2015 | 27,507.00 |
| Jun 30, 2015 | 104,948.00 |
| Mar 31, 2015 | 119,446.00 |
| Dec 31, 2014 | 494,066.00 |
| Sep 30, 2014 | 1.97 Mn |
| Jun 30, 2014 | 1.60 Mn |
| Mar 31, 2014 | 1.09 Mn |
| Dec 31, 2013 | 145,458.00 |
| Sep 30, 2013 | 156,198.00 |
| Jun 30, 2013 | 92,278.00 |
| Dec 31, 2012 | 606,158.00 |